Incretin hormones, principally glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), contribute to control of islet function. Their bioactivity is regulated by the enzymatic activity of dipeptidyl peptidase-4 (DPP-4), a widely expressed serine protease (Deacon, 2004...
Up to now DPP4 has gained most interest as a therapeutic target for type 2 diabetes treatment due to the degradation of the incretin hormone glucagon-like peptide (GLP)-1 by this enzyme. Thus, DPP4-inhibitors are able to prolong the insulinotropic effect of GLP-1 and are now in clinical ...
Dipeptidylpeptidase 4 (DPP4) inhibitors have clinical benefit in patients with type 2 diabetes mellitus by increasing levels of glucose-lowering incretin hormones, such as glucagon-like peptide -1 (GLP-1), a peptide with a short half life that is secreted for approximately 1 hour following a me...
DPP4 is involved in the endogenous control of glycemia, being physiologically or pharmacology related to the degradation of glucagon, glucagon-like peptide-1 (GLP-1) and -2 (GLP-2), gastric inhibitory peptide or glucose-dependent insulinotropic polypeptide (GIP), and gastrin-releasing peptide (GRP...
Recently, clinical trials proved the safety of gliptins in treating patients with type 2 DM. Gliptins are dipeptidyl-peptidase 4 (DPP4/CD26) inhibitors, which stabilize glucagon-like peptide-1 (GLP-1), thereby increasing the bioavailability of insulin. Moreover, blocking DPP4 results in increased...
The most recent therapeutic choices for the management of T2DM are dipeptidyl peptidase 4 (DPP-4) inhibitors, glucagon-like peptide 1 (GLP-1) receptor agonists and sodium鈥揼lucose cotransporter 2 (SGLT-2) inhibitors. In this article, we summarize the mechanism of action, the advantages and ...